{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"1.8","value":"1.8"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"4.6","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate the median PFS time and its 95% CI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRuxolitinib Phosphate: Given PO","id":"OG000","title":"Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRuxolitinib Phosphate: Given PO","id":"OG001","title":"Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the date of start of treatment to the date of event defined as the first documented progression or death due to any cause, assessed up to 60 months.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}